Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.
This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p=0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK. Electronic address: vitnoriega@hotmail.com.
Victor
V
Noriega
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
Harpreet
H
Kaur
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Stephen
S
Devereux
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
Jennifer
J
Byrne
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Robert
R
Marcus
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
Andrew
A
Haynes
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Deborah
D
Yallop
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
Andrew
A
McMillan
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Wendy
W
Ingram
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Anjum
A
Khan
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Michelle
M
Kenyon
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Victoria
V
Potter
Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
Nigel
N
Russell
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Ghulam J
GJ
Mufti
Department of Haematological Medicine, King's College London and Kings College Hospital, London, UK.
Antonio
A
Pagliuca
D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D017710:Lymphocyte Transfusion; D008224:Lymphoma, Follicular / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014184:Transplantation, Homologous
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab
Alemtuzumab; BEAM; Follicular lymphoma; Hematopoietic stem cell transplantation